An Emerging Entity: Pancreatic Adenocarcinoma Associated with a Known *BRCA* Mutation: Clinical Descriptors, Treatment Implications, and Future Directions

MAEVE A. LOWERY,^a DAVID P. KELSEN,^a ZSOFIA K. STADLER,^{a,b} KENNETH H. YU,^a YELENA Y. JANJIGIAN,^a EMMY LUDWIG,^c DAVID R. D'ADAMO,^a ERIN SALO-MULLEN,^b MARK E. ROBSON,^b PETER J. ALLEN,^d ROBERT C. KURTZ,^c EILEEN M. O'REILLY^a

^aGastrointestinal Oncology Service, ^bClinical Genetics Service, ^cGastroenterology Service, and

^dHepatopancreaticobiliary Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York, USA

Key Words. BRCA1 • BRCA2 • Pancreas adenocarcinoma • Genetics • PARP

Disclosures

Maeve A. Lowery: None; **David P. Kelsen:** None; **Zsafia K. Stadler:** None; **Kenneth H. Yu:** None; **Yelena Y. Janjigian:** Consultant/advisory role: Genentech; *Research funding/contracted research:* Boehringer Ingelheim; **Emmy Ludwig:** None; **David R. D'Adamo:** Consultant/advisory role: Novartis; *Honoraria:* Bayer, Novartis; *Research funding/contracted research:* Bayer, Genentech; **Erin Salo-Mullen:** None; **Mark E. Robson:** Consultant/advisory role: AstraZeneca, Abbott, sanofi-aventis; *Research funding/contracted research:* AstraZeneca; **Peter J. Allen:** None; **Robert C. Kurtz:** None; **Eileen M. O'Reilly:** *Research funding/contracted research:* AstraZeneca, KuDos Pharmaceuticals; *Consultant/advisory role:* Abbott Pharmaceuticals.

Section Editor **Richard Goldberg** discloses a consulting relationship with Amgen, Bayer, Genentech, Genomic Health, Lilly, and sanofi-aventis; and research funding from Amgen, Bayer, Genentech, sanofi-aventis, and Enzon.

Section Editor **Patrick Johnston** discloses employment with Almac Diagnostics; intellectual property rights in 12 patents; a consulting relationship with Almac, Roche, Chugai Pharmaceuticals, and sanofi-aventis; honoraria received from AstraZeneca, Chugai Pharmaceuticals, Pfizer, sanofi-aventis, and Roche; research funding from AstraZeneca and Amgen; and ownership interests in Almac Diagnostics and Fusion Antibodies.

Section Editor **Peter O'Dwyer** discloses a consulting relationship with Tetralogic Pharmaceuticals, PRECOG, and AstraZeneca; an advisory relationship with Tetralogic Pharmaceuticals, PRECOG, Onyx, sanofi-aventis, and Topotarget; research support from Pfizer, Bristol-Myers Squibb, Methylogene, Novartis, Genentech, Ardea, Exelixis, FibroGen, AstraZeneca, Incyte, ArQule, and GlaxoSmithKline; honoraria received from Genentech, Bristol-Myers Squibb, and Pfizer; and ownership interest with Tetralogic Pharmaceuticals.

Reviewer "A" discloses an ownership interest in Pharmacyclics and Jennerex.

The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. On the basis of disclosed information, all conflicts of interest have been resolved.

LEARNING OBJECTIVES

After completing this course, the reader will be able to:

1. Describe the genetic syndromes associated with pancreas adenocarcinoma.
2. Explain the potential role of platinum-based therapy and PARP inhibitors in BRCA-mutated pancreas adenocarcinoma.

ABSTRACT

Background. *BRCA1* and *BRCA2* germline mutations are associated with an elevated risk for pancreas adenocarcinoma (PAC). Other *BRCA*-associated cancers have been shown to have greater sensitivity to platinum and poly-(ADP-ribose) polymerase (PARP) inhibitors with better clinical outcomes than in sporadic cases; however, outcomes in *BRCA*-associated PAC have not been reported.

Methods. Patients with a known *BRCA1* or *BRCA2* mutation and a diagnosis of PAC were identified from the Gastrointestinal Oncology Service, Familial Pancreas Cancer Registry, and Clinical Genetics Service at Memorial Sloan-Kettering Cancer Center.

Results. Fifteen patients, five male, with a *BRCA1* ($n = 4$) or *BRCA2* ($n = 11$) mutation and PAC and one patient with a *BRCA1* mutation and acinar cell carcinoma of the pancreas were identified. Seven female patients (70%) had a prior history of breast cancer. Four patients received a PARP inhibitor alone or in combination with chemother-

apy; three demonstrated an initial radiographic partial response by Response Evaluation Criteria in Solid Tumors whereas one patient had stable disease for 6 months. Six patients received platinum-based chemotherapy first line for metastatic disease; five of those patients had a radiographic partial response.

Conclusion. *BRCA* mutation-associated PAC represents an underidentified, but clinically important, subgroup of patients. This is of particular relevance given the ongoing development of therapeutic agents targeting DNA repair, which may potentially offer a significant benefit to a genetically selected population. We anticipate that further study and understanding of the clinical and biologic features of *BRCA*-mutant PAC will aid in the identification of tissue biomarkers indicating defective tumor DNA repair pathways in sporadic PAC. *The Oncologist* 2011; 16:1397–1402

INTRODUCTION

Despite advances in the development of cytotoxic and targeted therapies, pancreatic adenocarcinoma (PAC) remains a significant cause of cancer mortality worldwide [1]. Although the majority of cases of PAC are sporadic, up to one in 10 cases occurs in the setting of a hereditary cancer predisposition syndrome, the most common of which is a germline *BRCA1* or *BRCA2* mutation [2]. The lifetime risk for PAC in a *BRCA2* mutation carrier is estimated at 3.5–10 times that of the general population [2, 3]. Recently, *BRCA1* was also implicated as carrying an elevated risk for the development of PAC, although this risk appears to be lower than that seen in *BRCA2* mutation carriers; the frequency of *BRCA1* mutations compared with *BRCA2* mutations in familial pancreatic cancer kindreds is also less [4]. There is currently no consensus regarding standard indications for *BRCA1* and *BRCA2* testing in patients with PAC.

Study of the clinical and pathologic features of sporadic serous ovarian and triple-negative breast cancers has shown significant overlap with that of *BRCA1* mutation-associated cases with the respective malignancy. Moreover, the presence of a germline *BRCA1* or *BRCA2* mutation has been identified as an independent predictive factor for overall survival in unselected advanced ovarian cancer patients [5]. In contrast, the literature to date regarding the clinical features of *BRCA* mutation-associated PAC is limited. The largest series to date of eight patients with a *BRCA1* or *BRCA2* mutation and PAC was reported from Memorial Sloan-Kettering Cancer Center (MSKCC) in 2009 and was limited to patients of Ashkenazi Jewish heritage with re-

sected PAC; data on response to systemic therapy and outcomes were not reported [6]. Defining and targeting tumors deficient in DNA repair have become increasingly important over recent years because of the ongoing development of novel therapeutic strategies with the ability to exploit tumor DNA repair abnormalities [7]. *BRCA* mutation-associated PAC represents a small, but clinically significant, group of patients who may potentially benefit from therapies synthetically lethal with a deficiency in homologous recombination; it is also possible that clinical outcomes may differ in this genetically selected population from outcomes in sporadic PAC.

To further explore these concepts, we identified 15 patients with a known *BRCA1* or *BRCA2* mutation and PAC seen at our institution over a 7-year period, representing the largest reported series of *BRCA* mutation-associated PAC to date.

PATIENTS AND METHODS

Patients with a known *BRCA1* or *BRCA2* mutation and PAC were identified from the prospectively collected MSKCC Pancreatic Cancer Family Registry and retrospectively from electronic records of the Clinical Genetics Service. Prior approval for the project was obtained from the institutional review/privacy board. None of the patients identified herein were included in the prior series of eight *BRCA* mutation-associated PAC cases published from our institution [6]. Clinical and pathological data were collected from chart review, including age at diagnosis, sex, epidemiologic information (where avail-

able), personal and family history of malignancy, presenting symptoms, tumor site, pathology/cytology results, date and type of operation, systemic therapy and/or radiation therapy, and status at last follow-up. Records were reviewed to determine treatment regimens and radiology results were reviewed to determine response to therapy. Overall survival was calculated from the date of cytological or pathological confirmation of diagnosis to the date of death or last follow-up, and was calculated using the Kaplan–Meier method.

RESULTS

Fifteen patients with a *BRCA* germline mutation and PAC were identified. Four patients (27%) had a *BRCA1* mutation identified and 11 (73%) had a *BRCA2* mutation. Eight (53%) patients had Jewish heritage, nine (60%) had a prior history of malignancy, and 12 (80%) had a first-degree relative with breast, ovarian, prostate, or pancreatic cancer. Figure 1 shows a family pedigree from a 36-year-old Asian male *BRCA1* mutation carrier with PAC. Seven female patients (70%) had a prior history of breast cancer; other prior malignant diagnoses included squamous cell carcinoma of the tonsil, papillary thyroid carcinoma, and melanoma. The clinicopathologic features of patients with a *BRCA* mutation and PAC are summarized in Table 1. One additional patient with an acinar cell pancreas malignancy and a *BRCA1* mutation was also identified.

Five patients (33%) had localized, operable disease at presentation; the remainder had locally advanced ($n = 2$, 14%) or metastatic ($n = 8$, 53%) disease. All patients had recurred at the time of last follow-up; nine (60%) were alive with disease and six (40%) had died as a result of progressive PAC. The median overall survival time for all 15 patients was 27.6 months. Three patients received a poly(ADP-ribose) polymerase (PARP) inhibitor in combination with chemotherapy; two demonstrated an initial radiographic partial response by the Response Evaluation Criteria in Solid Tumors (RECIST) with subsequent progression of disease at 5 months and 6 months, whereas the third patient had stable disease as the best response. Figure 2 demonstrates a radiographic partial response to gemcitabine in combination with a PARP inhibitor. One patient received a PARP inhibitor as single-agent therapy for metastatic disease and demonstrated a partial radiographic response to therapy. Six patients received platinum-based chemotherapy as first-line therapy for metastatic disease; five of those patients had a radiographic partial response by the RECIST, including one patient with a complete response to infusional 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan. Treatment history, including the radio-

graphic best response, and survival outcomes are summarized in Table 2.

DISCUSSION

Germline mutations in *BRCA1* and *BRCA2* are estimated to occur in up to 7% of patients with PAC, whereas in patients with familial PAC, the frequency of *BRCA1* or *BRCA2* mutation carriers is estimated at 11%–17% [2]. All but one of the 15 patients we identified as carrying a *BRCA1* or *BRCA2* germline mutation had either a personal history of a prior malignancy or a documented case of *BRCA*-associated malignancy in a first-degree relative, which may reflect the biased sample assessed in that such observations prompted referral for genetic testing. However, it is worth noting that seven of the 10 female carriers identified had a prior history of breast cancer. The median age at diagnosis of PAC was 62 years, 10 years below the average age at diagnosis in an unselected population reported from the Surveillance, Epidemiology, and End Results (SEER) data.

One patient with acinar cell carcinoma of the pancreas, a rare histological subtype of pancreatic malignancy, and a *BRCA1* mutation was identified; an association between these two conditions has not been described previously. That patient had a complex past medical history with prior diagnoses including acromegaly, colonic adenocarcinoma, and papillary renal cell carcinoma and reported a significant family history of early-onset breast cancer in multiple first- and second-degree relatives. Colon cancer, thyroid cancer, and renal cell cancer have not been demonstrated to occur at significantly higher rates in *BRCA1* or *BRCA2* mutation carriers [8].

Over 6,000 patients were evaluated at MSKCC with a diagnosis of PAC in 2000–2010; the identification of 15 *BRCA1* or *BRCA2* mutation carriers and PAC in 2003–2010 is likely to be a substantial underestimation of the true frequency of mutation carriers in this population because the vast majority of patients do not undergo genetic testing. In a prior study at our institution of 38 breast cancer survivors who subsequently developed PAC, just two of the 38 women in that group had undergone *BRCA1* or *BRCA2* testing [9]. In contrast to breast and ovarian cancers, for which referral for genetic counseling and testing is routine, the majority of patients with PAC and a personal or family history suggestive of *BRCA* mutation do not undergo genetic testing. Several barriers to genetic testing in this population exist, including a lack of awareness of the association between *BRCA* mutation and PAC among treating professionals and patients, difficulty in obtaining reimbursement for the cost of genetic testing, and rapid disease progression precluding attendance for genetic counseling and testing. With greater recognition, better access, and a more rapid turnaround time for *BRCA* genetic testing, we anticipate that in the

Figure 1. Family pedigree of a patient with a *BRCA1* mutation and pancreatic adenocarcinoma.
Note: Pedigree was altered to protect the confidentiality and privacy of family members without compromising relevant content.

Table 1. Demographic data for patients with a <i>BRCA</i> mutation and pancreatic adenocarcinoma	
Patients with <i>BRCA</i> mutation and pancreatic adenocarcinoma (n = 15)	
Male	5 (33%)
Female	10 (67%)
Median age at diagnosis	62 yrs
Jewish heritage	8 (53%)
No Jewish heritage	7 (47%)
Primary tumor location	
Head of pancreas	9 (60%)
Body/tail of pancreas	6 (40%)
Stage at diagnosis	
Operable	5 (33%)
Locally advanced	2 (14%)
Metastatic	8 (53%)
Personal history of malignancy (any)	9 (60%)
No prior history of malignancy	6 (40%)
Personal history of breast cancer (all female)	7 (70%)
First-degree relative with breast, pancreas, prostate, or ovarian cancer	12 (80%)

near future at least some of these current barriers to genetic counseling and testing for PAC patients can be overcome.

In this series of *BRCA* mutation–associated PAC patients, clinical and partial radiologic responses were seen in two of the three patients treated with the combination of a PARP inhibitor and gemcitabine, and one additional patient had a partial radiographic response to single-agent PARP inhibitor treatment. Five of six patients (83%) treated with platinum-based first-line chemotherapy for metastatic disease demonstrated a radiographic complete or partial response by the RECIST. This observation lends support to the hypothesis that

Figure 2. Patient with stage IV pancreas adenocarcinoma and a *BRCA1* mutation: Response to gemcitabine plus a poly-(ADP-ribose) polymerase inhibitor.

PARP inhibitors are synthetically lethal in *BRCA*-deficient PAC. PARP-1 and PARP-2 are key components of the cellular DNA repair mechanism for single-strand breaks and nucleoside base damage; inhibition of PARP in tumor cells leads to transformation of background single-strand breaks into double-strand breaks (DSBs) [10]. These lesions are cytotoxic in cells without functional *BRCA1* or *BRCA2* because they are unable to effectively repair DSBs by homologous recombination and instead rely on the error-prone nonhomologous end-joining repair mechanism. Platinum chemotherapy drugs exert their cytotoxic effect by binding directly to DNA, causing crosslinking of DNA strands and thereby inducing DNA DSBs, which also are ineffectively repaired in cells lacking functioning *BRCA1* or *BRCA2*. Pancreatic cancer cell lines deficient in *BRCA2* or another component of the Fanconi ane-

Table 2. *BRCA* mutation carriers with pancreas adenocarcinoma

Patient no.	Stage	<i>BRCA</i> mutation	First line	Response	Second line	Response	Third line	Response	OS (mos)
1	T2N0M0	<i>BRCA1</i>	Surgery and adjuvant gemcitabine	Relapse, 16.3 mos	PARP inhibitor and gemcitabine	PR, 2 mos; POD, 4.5 mos	FOLFIRINOX	Assessment pending	24.7, AWD
2	T3N0M0	<i>BRCA2</i>	Surgery and adjuvant GTX	Relapse, 12.8 mos	Pending				13.4, AWD
3	T3, N0, II	<i>BRCA2</i> *7535delA	Surgery and adjuvant gemcitabine	Relapse, 11 mos	FOLFIRINOX–FOLFOX	CR, 3 mo; dose d/c for toxicity; LR, 8 mos	Cisplatin/5-FU–capecitabine, RT	PR	38.4, AWD
4	T3, N1, IIB	<i>BRCA2</i> *4075DGT	Surgery and adjuvant gemcitabine and cisplatin	Relapse at 14 mos	PARP inhibitor	PR, 6 mos			20.7, AWD
5	T3, N1, IIB	<i>BRCA2</i>	Surgery and adjuvant gemcitabine, 5-FU + RT	Relapse at 13 mo	Gem/oxaliplatin	PR; POD, 6 mos	PARP inhibitor	SD, 6 mos	34.3, AWD
6	T4, III	<i>BRCA2</i> Y1894X	GTX	POD at 5 mos	FOLFOX	Response at 3 mos			8.8, AWD
7	T4, III	<i>BRCA2</i>	Gemcitabine and cisplatin → gemcitabine and RT → gemcitabine	SD/minor response; POD, 11 mos	FOLFOX	POD, 2 mos	FOLFIRI	POD, 2 mos	20.4, DOD
8	IV	<i>BRCA2</i> *6174delT	Unknown	POD at 7 mos					9.1, DOD
9	IV	<i>BRCA1</i> *4603G->T	Gemcitabine and capecitabine	PR, 3 mos; SD, 6 mos; RFA + surgery	FOLFOX	POD, 2 mos	Flavopiridol and docetaxel	POD, 2 mos	27.6, DOD
10	IV	<i>BRCA1</i> *187delAG	Gemcitabine + PARP inhibitor	PR 2 mo, POD 6 m	FOLFOX [narrow CPT-11 + gemcitabine (oxaliplatin d/c reaction)]	POD, 2.5 mos	PARP inhibitor and temozolamide (1 cycle)	POD, 6 wks	13.7, DOD
11	IV	<i>BRCA2</i>	No treatment						1.0, DOD
12	IV	<i>BRCA1</i> *IVS8+7G>A	Gemcitabine and PARP inhibitor	PR; POD, 7 mos	Gemcitabine and capecitabine	POD, 2 mos	FOLFOX	POD	11.5, DOD
13	IV	<i>BRCA2</i>	Gemcitabine and cisplatin	PR; POD, 9 mos	FOLFOX	POD, 2 mos	MK 2206	POD, 2 mos	15.2, AWD
14	IV	<i>BRCA2</i> IVS13 -2A>T, V211I (859 G>A)	Gemcitabine and oxaliplatin	PR; SD, 7 mos					9.2, AWD
15	IV	<i>BRCA2</i>	Gemcitabine and oxaliplatin	Pending					1.5, AWD

Abbreviations: 5-FU, 5-fluorouracil; AWD, alive with disease; d/c discontinued; DOD, dead of disease; FOLFIRI, 5-FU, leucovorin, and irinotecan; FOLFIRINOX, 5-FU, leucovorin, oxaliplatin, and irinotecan; FOLFOX, 5-FU, leucovorin, and oxaliplatin; GTX, gemcitabine, docetaxel, and capecitabine; LR, local recurrence; PARP, poly(ADP-ribose) polymerase; POD, progression of disease; PR, partial response; RFA, radiofrequency ablation; RT, radiotherapy; SD, stable disease.

Table 3. Trials of PARP inhibitors including pancreas adenocarcinoma patients

Phase	Drug	Design	Combination	<i>n</i>	NCI
II	BSI-201	Single arm, <i>BRCA2</i> only	Gemcitabine		NCT00422682
II	AZD-2281	Single-arm, <i>BRCA1</i> , <i>BRCA2</i> only		300	NCT01078662
II	AZD2281	Single-arm, phase II	Gemcitabine	70	NCT00515866
II	AZD-2281	Untreated disease, randomized phase II	Irinotecan, mitomycin, cisplatin with or without AZD-2281		
II	ABT-888	Second-line therapy, single arm	FOLFOX		

Abbreviations: FOLFOX, 5-fluorouracil, leucovorin, and oxaliplatin; NCI, National Cancer Institute; PARP, poly(ADP-ribose) polymerase.

mia pathway have been shown to have marked sensitivity to DNA crosslinking agents [11]. Previous anecdotal reports also indicate a substantial response to alkylating agents in patients with a known *BRCA* mutation and PAC [12]. Notably, all patients treated with a PARP inhibitor experienced progression of disease after several months of therapy, despite an initial clinical and radiographic response. The mechanism of acquired resistance in vivo to PARP inhibition is unknown, but it may potentially occur as a result of a secondary mutation re-

sulting in restored competency of homologous repair in *BRCA*-mutant cells [13].

Interpretation of survival outcomes in this series is limited by the small number of patients and varying stages of disease at presentation. The possibility of survival bias must also be considered because patients who live longer are more likely to present for genetic testing. In this cohort of 15 patients, only five of whom underwent surgical resection, the overall median survival duration for the cohort was

27.6 months. Although this appears better than the reported SEER survival data in unselected PAC cases [1], the prognostic significance of *BRCA* mutation remains unclear.

We believe that there is a strong therapeutic rationale for the development of PARP inhibitors for *BRCA1* or *BRCA2* mutation-associated PAC. In collaboration with other investigators and in partnership with the Cancer Therapeutic and Evaluation Program and the Lustgarten Foundation, we plan a randomized phase II trial evaluating the addition of PARP inhibition to platinum-based therapy in a genetically selected population of *BRCA1*, *BRCA2*, or *PALB2* mutation carriers with PAC. Selected other PARP inhibitor trials in pancreas cancer are noted in Table 3.

In conclusion, *BRCA* mutation-associated PAC represents an underidentified, but clinically important, subgroup of patients. Improved awareness of the association between *BRCA* mutation and PAC among patients and physicians is important to identify potential mutation carriers on the basis of a family or personal history of malignancy or a predis-

posing genetic background. This is of particular relevance given the ongoing development of therapeutic agents targeting DNA repair, which may potentially offer a significant benefit to a genetically selected population and provide a first “proof of principle” of a targeted therapy approach in PAC patients. We anticipate that further study and understanding of the clinical and biologic features of *BRCA*-mutant PAC will aid in the identification and refinement of tissue biomarkers indicating defective tumor DNA repair pathways in sporadic PAC cases.

AUTHOR CONTRIBUTIONS

Conception/Design: Eileen M. O'Reilly, Maeve A. Lowery, David Kelsen, Kenneth Yu, Zsafia Stadler, Emmy Ludwig, Erin Salo-Mullen, Mark Robson, Peter J. Allen, Robert C. Kurtz, David R. D'Adamo

Provision of study material or patients: Eileen M. O'Reilly, Maeve A. Lowery, David Kelsen, Kenneth Yu, Zsafia Stadler, Yelena Y. Janjigian, Emmy Ludwig, Erin Salo-Mullen, Mark Robson, Peter J. Allen, Robert C. Kurtz, David R. D'Adamo

Collection and/or assembly of data: Eileen M. O'Reilly, Maeve A. Lowery

Data analysis and interpretation: Eileen M. O'Reilly, Maeve A. Lowery

Manuscript writing: Maeve A. Lowery

Final approval of manuscript: Eileen M. O'Reilly, David Kelsen, Kenneth Yu, Zsafia Stadler, Yelena Y. Janjigian, Emmy Ludwig, Erin Salo-Mullen, Mark Robson, Peter J. Allen, Robert C. Kurtz, David R. D'Adamo

REFERENCES

- 1 Jemal A, Siegel R, Ward E et al. Cancer statistics, 2009. *CA Cancer J Clin* 2009;59:225–249.
- 2 Hahn SA, Greenhalf B, Ellis I et al. *BRCA2* germline mutations in familial pancreatic carcinoma. *J Natl Cancer Inst* 2003;95:214–221.
- 3 The Breast Cancer Linkage Consortium. Cancer risks in *BRCA2* mutation carriers. *J. Natl. Cancer Inst* 1999;91:1310–1316.
- 4 Brose MS, Rebbeck TR, Calzone KA et al. Cancer risk estimates for *BRCA1* mutation carriers identified in a risk evaluation program. *J Natl Cancer Inst* 2002;94:1365–1372.
- 5 Lacour RA, Westin SN, Meyer LA et al. Improved survival in non-Ashkenazi Jewish ovarian cancer patients with *BRCA1* and *BRCA2* gene mutations. *Gynecol Oncol* 2011;121:358–363.
- 6 Ferrone CR, Levine DA, Tang LH et al. *BRCA* germline mutations in Jewish patients with pancreatic adenocarcinoma. *J Clin Oncol* 2009;27:433–438.
- 7 Ashworth A. A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. *J Clin Oncol* 2008;26:3785–3790.
- 8 Risch HA, McLaughlin JR, Cole DE et al. Population *BRCA1* and *BRCA2* mutation frequencies and cancer penetrances: A kin-cohort study in Ontario, Canada. *J Natl Cancer Inst* 2006;98:1694–1706.
- 9 Lowery MA, Stadler ZK, Ludwig Miller E et al. Clinical outcomes in pancreatic adenocarcinoma (PAC) in breast cancer (BC) survivors. *J Clin Oncol* 2010;28(15 suppl):4152.
- 10 Sandhu SK, Yap TA, de Bono JS. Poly(ADP-ribose) polymerase inhibitors in cancer treatment: A clinical perspective. *Eur J Cancer* 2010;46:9–20.
- 11 McCabe N, Lord CJ, Tutt AN et al. *BRCA2*-deficient CAPAN-1 cells are extremely sensitive to the inhibition of poly(ADP-ribose) polymerase: An issue of potency. *Cancer Biol Ther* 2005;4:934–936.
- 12 Chalasani P, Kurtin S, Dragovich T. Response to a third-line mitomycin C (MMC)-based chemotherapy in a patient with metastatic pancreatic adenocarcinoma carrying germline *BRCA2* mutation. *JOP* 2008;9:305–308.
- 13 Edwards SL, Brough R, Lord CJ et al. Resistance to therapy caused by intragenic deletion in *BRCA2*. *Nature* 2008;451:1111–1115.